Results 31 to 40 of about 9,978 (177)
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network (EMN)
American Journal of Hematology, Volume 101, Issue 9, Page 2353-2370, September 2026.Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.Heinz Ludwig, Evangelos Terpos, Francesca Gay, Niels W. C. J. van de Donk, Sarah Bernhard, Monika Engelhardt, Gordon Cook, Fredrik Schjesvold, Hermann Einsele, Graham Jackson, Charlotte Pawlyn, María‐Victoria Mateos, Sonja Zweegman, Martin Schreder, Meral Beksaç, Christoph Driessen, Enrique M. Ocio, Rakesh Popat, Leo Rasche, Cyrille Touzeau, Pellegrino Musto, Annemiek Broijl, Meletios Dimopoulos, Roman Hajek, Mario Boccadoro, Pieter Sonneveld +25 morewiley +1 more sourceQuizartinib in Combination With FLAG‐IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG‐QUIDA): A PETHEMA Phase I‐II Trial
American Journal of Hematology, Volume 101, Issue 9, Page 2258-2268, September 2026.ABSTRACT
Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.Teresa Bernal, Javier Zambrano Márquez, Rebeca Rodríguez‐Veiga, Eduardo Rodríguez‐Arbolí, Juan Manuel Bergua‐Burgués, Susana Vives, Montserrat Arnán, Pilar Martínez Sánchez, Pilar Herrera‐Puente, Josefina Serrano‐López, Vicente Rubio, Inmaculada Marchante‐Cepillo, Marta Cervera‐Calvo, Andrés Novo García, Rosa Fernández Martín, Cristina Gil Cortés, Carlos Rodríguez‐Medina, Victor Noriega‐Concepción, Ana Alfonso‐Piérola, Carmen Loredo, María Antuña‐Casal, Blanca Boluda, Isabel Cano‐Ferri, Evelyn Acuña‐Cruz, Laura Torres‐Miñana, Joaquín Sánchez‐García, Cristina Bilbao, Maria Teresa Gómez‐Casares, David Martínez Cuadrón, Pau Montesinos +29 morewiley +1 more sourceParticipation and Follow‐Up Compliance in Cervical Cancer Screening According to Delivery Strategy for HPV Self‐Collection: A Community Trial in Underserved Colombian Areas
Cancer Medicine, Volume 15, Issue 8, August 2026.ABSTRACT
Low‐ and middle‐income countries (LMIC) continue to bear a high burden of cervical cancer (CC). Women's participation in CC screening is challenging in LMICs, but self‐collection of HPV tests has shown increased participation in controlled trials.Ginna Fernández‐Deaza, Natascha Ortíz, Alexander Salazar, Angélica Parra, Carolina Morante‐Caicedo, Mario Rodríguez, Juan David Toca, Maria Alejandra Arria, Ana Karina Ceballos, Juliana Rodríguez, Diana Acosta, Raúl Murillo +11 morewiley +1 more sourceRituximab Binding Endows CD20+ Extracellular Vesicles With NK Cell‐Activating Properties in B Cell Lymphoma
Journal of Extracellular Vesicles, Volume 15, Issue 8, August 2026.B cell lymphoma‐derived EVs are intrinsically neutral or suppressive with respect to NK cell activity (panel 1). In the context of rituximab treatment, NK cytotoxicity is enhanced by antibody‐dependent cell‐mediated cytotoxicity (panel 2). Herein we show that, in addition, rituximab recognition of EV‐associated CD20 generates immune complexes that ...Adrián V. Otero, Paula Soledad Pérez, Belen Gaete‐Ramírez, Gregorio Cordini, Matías Norte, Enriqueta Martínez, Nicolás Marsol, Cecilia Malusardi, Sofía Rivarola, Ana Cantillo, María Luz Leicaj, Constanza Russo, Juan Quarroz Braghini, Federico Penas, Glenda Ernst, Cecilia Cabral, Silvina Palmer, Manuel Varas‐Godoy, Lourdes Arruvito, Matías Ostrowski +19 morewiley +1 more sourceRegional Standardization of CLL Management: Results of a Delphi Consensus Process
European Journal of Haematology, Volume 117, Issue 2, Page 442-447, August 2026.ABSTRACT
The therapeutic landscape of chronic lymphocytic leukemia (CLL) has been profoundly transformed by the introduction of Bruton tyrosine kinase and BCL‐2 inhibitors. Despite improved survival outcomes, treatment selection remains complex, particularly in older patients with comorbidities, frailty, and increased infectious vulnerability.Enrica Antonia Martino, Annalisa Chiarenza, Salvatrice Mancuso, Marco Rossi, Caterina Stelitano, Ignazio Abbene, Sergio Cabibbo, Daniele Caracciolo, Emilia Cotzia, Amalia Figuera, Antonino Greco, Vanessa Innao, Luciano Levato, Carla Marino, Giuseppe Mineo, Laura Nocilli, Giuseppa Penna, Marika Porrazzo, Giorgio Tona, Ernesto Vigna, Fortunato Morabito, Daniela D'Angela, Massimo Gentile +22 morewiley +1 more sourceReal‐World Outcomes of FLAG‐Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study
American Journal of Hematology, Volume 101, Issue 7, Page 1692-1705, July 2026.ABSTRACT
In a large multicenter real‐world cohort, we aimed to evaluate outcomes of FLAG‐Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998–2024), including patients with primary ...Gaspar Aspas Requena, Rebeca Rodríguez‐Veiga, Cristina Gil, Carmen Botella, Eliana Aguiar, Fernanda Trigo, Mercedes Colorado, Teresa del Bernal del Castillo, Eva Barragan, Mar Tormo, Eduardo Rodríguez Arbolí, Josefina Serrano López, Raimundo García Boyero, Tamara Castaño, Pilar Herrera Puente, Mónica A. Romero Riquelme, María J. Sayas Lloris, Lorenzo Algarra‐Algarra, Carlos Rodriguez‐Medina, Claudia L. Sossa Melo, Jorge Labrador Gomez, Susana Vives, Olga Salamero, María Luz Amigo, Marta Valero Nuñez, Christine Rojas, Francisca Bass, María García‐Fortes, Belén Vidriales Vicente, Marta Polo, Celina Benavente, María D. Madrigal, Marcela Espinoza, Manuel Pérez‐Encinas, María L. Amador Barciela, Guiomar Bautista, Antonio Solana‐Altabella, Isabel Cano‐Ferri, Rafael Colmenares, Patricia García‐Ramírez, Francisco Ibáñez Alis, Manuel Barrios García, Gabriela Rodríguez‐Macías, Miguel López, Ana Yurena Oliva Hernández, Carlos Javier Cerveró, David Martínez‐Cuadrón, Pedro Chorão, Juan M. Bergua Burgues, Pau Montesinos +49 morewiley +1 more sourceMultiple myeloma: A tale of deregulated transcription factors
HemaSphere, Volume 10, Issue 7, July 2026.Abstract
A comprehensive understanding of the molecular mechanisms underlying multiple myeloma (MM) pathogenesis is essential for developing therapeutic strategies that overcome disease heterogeneity and treatment relapse. In this review, we focus on transcription factors (TFs), key regulators of gene expression that play critical roles in normal ...Nahia Gómez‐Echarte, Edurne San José‐Enériz, Estíbaliz Urizar‐Compains, Paula Rodriguez‐Otero, Felipe Prósper, Xabier Agirre +5 morewiley +1 more sourceOnco-hematologia: perspectivas e avanços
Research, Society and Development, 2020 O presente estudo observou relatar os avanços em Onco-hematologia, área que cuidam das doenças malignas do sangue, estas doenças exigem tratamento específico, com avançados equipamentos e exames para cuidar de cada uma dessas patologias, que vai de exame de sangue ao Transplante de Medula Óssea.Hyan Ribeiro da Silva, José Chagas Pinheiro Neto, Catarina Lopes Portela, Jemima Silva Kretli, Denise Coelho de Almeida, Gabriela Coutinho Amorim Carneiro, Ionara Rosa Soares da Cunha, Mateus Sena Lira, André Felipe de Castro Pereira Chaves, Daniella Farias Almeida, Álvaro Sepúlveda Carvalho Rocha, Nadia Maia Pereira, Fábio Dias Nogueira, Leonel Ferreira de Aguiar, Gerson Tavares Pessoa +14 moreopenaire +2 more sourcesSwitching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety
HemaSphere, Volume 10, Issue 7, July 2026.Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra‐orphan disease. In 2026, approved complement inhibitors (CIs) for PNH include three C5 inhibitors (C5i) and three proximal inhibitors (PIs). Clinical trials for the approved PI pegcetacoplan, iptacopan, and C5i + danicopan had clear protocols for changing from terminal to PI, extrapolated ...Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard J. Kelly, Roochi Trikha, Yasutaka Ueda, Jun‐ichi Nishimura, Christopher J. Patriquin, Alexander Röth, Petra Muus, Jens Panse, Miguel Gómez Álvarez, Alexandra Pike, Talha Munir, Shreyans Gandhi, Austin Kulasekararaj +15 morewiley +1 more sourcePB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
HemaSphere, 2022 M. J. Ramos, R. Peixeiro, L. Regadas, C. Pedrosa, P. Seabra, A. Mota, R. Cabral, R. Coutinho, L. Xavier, C. Casais, J. Rodrigues, I. Freitas, C. Gonçalves +12 moredoaj +1 more source
